Glycogen storage disease type I natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
Line 12: Line 12:
==Complications==
==Complications==
Common complications of glycogen storage disease type I include:<ref name="pmid12373567">{{cite journal |vauthors=Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP |title=Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I) |journal=Eur. J. Pediatr. |volume=161 Suppl 1 |issue= |pages=S20–34 |year=2002 |pmid=12373567 |doi=10.1007/s00431-002-0999-4 |url=}}</ref><ref>Bali DS, Chen YT, Austin S, et al. Glycogen Storage Disease Type I. 2006 Apr 19 [Updated 2016 Aug 25]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1312/
Common complications of glycogen storage disease type I include:<ref name="pmid12373567">{{cite journal |vauthors=Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP |title=Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I) |journal=Eur. J. Pediatr. |volume=161 Suppl 1 |issue= |pages=S20–34 |year=2002 |pmid=12373567 |doi=10.1007/s00431-002-0999-4 |url=}}</ref><ref>Bali DS, Chen YT, Austin S, et al. Glycogen Storage Disease Type I. 2006 Apr 19 [Updated 2016 Aug 25]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1312/
</ref>
</ref><ref name="KishnaniAustin2014">{{cite journal|last1=Kishnani|first1=Priya S.|last2=Austin|first2=Stephanie L.|last3=Abdenur|first3=Jose E.|last4=Arn|first4=Pamela|last5=Bali|first5=Deeksha S.|last6=Boney|first6=Anne|last7=Chung|first7=Wendy K.|last8=Dagli|first8=Aditi I.|last9=Dale|first9=David|last10=Koeberl|first10=Dwight|last11=Somers|first11=Michael J.|last12=Burns Wechsler|first12=Stephanie|last13=Weinstein|first13=David A.|last14=Wolfsdorf|first14=Joseph I.|last15=Watson|first15=Michael S.|title=Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics|journal=Genetics in Medicine|year=2014|issn=1098-3600|doi=10.1038/gim.2014.128}}</ref>
*Bleeding tendency due to impaired platelet function
*Bleeding tendency due to impaired platelet function
*Pancreatitis due to hypertriglyceridemia
*Pancreatitis due to hypertriglyceridemia
Line 23: Line 23:
*Splenomegaly (particularly in GSD type 1b)
*Splenomegaly (particularly in GSD type 1b)
*Hepatic adenoma with potential for malignant transformation
*Hepatic adenoma with potential for malignant transformation
*Anemia (especially in patients with hepatic adenoma)
*Osteoporosis
*Osteoporosis
*Delayed puberty
*Delayed puberty

Revision as of 18:31, 2 November 2017

Glycogen storage disease type I Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Glycogen storage disease type I from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Glycogen storage disease type I natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Glycogen storage disease type I natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Glycogen storage disease type I natural history, complications and prognosis

CDC on Glycogen storage disease type I natural history, complications and prognosis

Glycogen storage disease type I natural history, complications and prognosis in the news

Blogs on Glycogen storage disease type I natural history, complications and prognosis

Directions to Hospitals Treating Glycogen storage disease type I

Risk calculators and risk factors for Glycogen storage disease type I natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Natural History

  • GST type 1 presents first as an average age of 6 months (1 - 12 months).[1]
  • If left untreated, glycogen storage diseases develop complications including protruding abdomen due to marked hepatomegaly (storage of glycogen and fat), short stature, truncal obesity, rounded doll-like face, and wasted muscles.
  • Untreated patients usually have a cushingoid appearance due to short stature with a round face and full cheeks.[2]

Complications

Common complications of glycogen storage disease type I include:[1][3][2]

  • Bleeding tendency due to impaired platelet function
  • Pancreatitis due to hypertriglyceridemia
  • Cholelithiasis due to hypertriglyceridemia
  • Gout arthritis due to hyperuricemia
  • Nephrolithiasis and nephrocalcinosis due to hyperuricemia
  • Asymptomatic anemia
  • Osteopenia leading to pathologic fractures
  • Rickets
  • Splenomegaly (particularly in GSD type 1b)
  • Hepatic adenoma with potential for malignant transformation
  • Anemia (especially in patients with hepatic adenoma)
  • Osteoporosis
  • Delayed puberty
  • Pulmonary hypertension
  • Polycystic ovaries
  • Changes in brain function

Prognosis

  • If left untreated, patients with GSD I develops complications and dies in infancy or childhood of overwhelming hypoglycemia and acidosis.
  • Surviving individuals have stunted physical growth and delayed puberty due to chronically low insulin levels.
  • Mental retardation as a result of severe and recurrent hypoglycemia is considered preventable with appropriate treatment.

References

  1. 1.0 1.1 Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP (2002). "Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I)". Eur. J. Pediatr. 161 Suppl 1: S20–34. doi:10.1007/s00431-002-0999-4. PMID 12373567.
  2. 2.0 2.1 Kishnani, Priya S.; Austin, Stephanie L.; Abdenur, Jose E.; Arn, Pamela; Bali, Deeksha S.; Boney, Anne; Chung, Wendy K.; Dagli, Aditi I.; Dale, David; Koeberl, Dwight; Somers, Michael J.; Burns Wechsler, Stephanie; Weinstein, David A.; Wolfsdorf, Joseph I.; Watson, Michael S. (2014). "Diagnosis and management of glycogen storage disease type I: a practice guideline of the American College of Medical Genetics and Genomics". Genetics in Medicine. doi:10.1038/gim.2014.128. ISSN 1098-3600.
  3. Bali DS, Chen YT, Austin S, et al. Glycogen Storage Disease Type I. 2006 Apr 19 [Updated 2016 Aug 25]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2017. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1312/

Template:WS Template:WH